The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of surgery"
DOI: 10.1097/js9.0000000000000314
Abstract: BACKGROUND The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains controversial. In addition, several unanswered questions regarding the use of CN remain: Can CN provide survival benefits for patients with mRCC?… read more here.
Keywords: cytoreductive nephrectomy; role cytoreductive; therapy; patients mrcc ... See more keywords
Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.8_suppl.66
Abstract: 66 Background: Patients with mRCC with S/R components tend to have a poor prognosis with few therapeutic options available. Recent data suggest that immune checkpoint inhibitor (ICI)-based therapies may be especially effective for these patients.… read more here.
Keywords: patients mrcc; based therapies; first line; ici based ... See more keywords
High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0190084
Abstract: Background High-dose interleukin-2 (HD IL-2) is used in the treatment of metastatic renal cell carcinoma (mRCC) and has an overall response rate (ORR) of 12–20% and a complete response rate (CR) of 8% in unselected… read more here.
Keywords: renal cell; cell carcinoma; mrcc sarcomatoid; patients mrcc ... See more keywords